Coronary imaging developer InfraReDx has enrolled the first patient in its phase II clinical trial to evaluate image guidance by its LipiScan intravascular ultrasound and near-infrared spectroscopy system.
The trial, called CANARY (Coronary Assessment by Near-Infrared of Atherosclerotic Rupture-Prone Yellow), will test the hypothesis that near-infrared-guided use of an embolic protection device, or filter, during percutaneous coronary intervention can reduce the rate of periprocedural heart attacks in patients identified as having high-risk lipid-core plaques, InfraReDx said.
The prospective, multicenter, randomized, open-label phase II trial is expected to enroll 108 patients at 10 U.S. clinical sites, according to the company.
